Antibiotic and antifungal treatment among persons with confirmed coccidioidomycosis — Southern California, 2011

Gloria C. Chi1,2, Kaitlin Benedict3, Karlyn D. Beer3, Brendan R. Jackson3, Orion McCotter3, Fagen Xie2, Jean M. Lawrence2 and Sara Y. Tartof2,∗

1Epidemic Intelligence Service, Division of Scientific Education and Professional Development, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, 2Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA and 3Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA

∗To whom correspondence should be addressed. Sara Y. Tartof, PhD, MPH, Kaiser Permanente Southern California, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA 91101, Tel: 626-564-3001; E-mail: Sara.Y.Tartof@kp.org

Received 13 April 2019; Revised 24 May 2019; Accepted 17 June 2019; Editorial Decision 3 June 2019

Abstract

We investigated coccidioidomycosis testing and treatment patterns among persons in an integrated healthcare delivery system to identify gaps in diagnosis and treatment. Coccidioidomycosis diagnosis delays were common. Among persons who tested positive, 70% were prescribed antibiotics before positive coccidioidomycosis tests. Antibiotic treatment decreased and antifungal treatment increased after positive testing.

Key words: coccidioidomycosis, antibiotics, antifungals, treatment, electronic health records.

Coccidioidomycosis (Valley fever) is caused by inhalation of aerosolized spores from the soil-dwelling fungus Coccidioides.1 Coccidioidomycosis is endemic in the western United States.2 Approximately 40% of coccidioidomycosis infections are symptomatic, and clinical presentations are typically indistinguishable from those of common bacterial and viral respiratory infections.2 Thus, clinicians might not initially suspect coccidioidomycosis, which can lead to limited testing and delayed or missed diagnosis.3 Misdiagnosis of coccidioidomycosis as bacterial pneumonia can lead to unnecessary antibiotic use, which can contribute to antimicrobial resistance and other adverse consequences.4 Moreover, misdiagnosis can lead to treatment delays or non-treatment, which might be particularly harmful for persons with risk factors for severe disease.1

We investigated coccidioidomycosis testing and antimicrobial treatment patterns at Kaiser Permanente Southern California (KPSC), a large, integrated healthcare delivery system, to identify opportunities to promote judicious antibiotics use.

KPSC serves >4.5 million members who are representative of southern California’s population.5 We identified coccidioidomycosis cases from positive laboratory tests from January 1 to December 31, 2011, documented in KPSC electronic health records (EHRs). We excluded persons who had coccidioidomycosis International Classification of Disease, Ninth Revision, Clinical Modification diagnosis codes in the year before their first positive test. KPSC’s testing algorithm typically involves screening with enzyme immunoassay, with subsequent automatic reflex testing for positives off-site by immunodiffusion, complement fixation, or both to confirm the diagnosis. Cases were also identified by culture or histological report identifying Coccidioides spp.

We queried EHRs to identify health care events, including coccidioidomycosis tests and antimicrobial prescriptions. We identified the specimen collection date of the first of any positive coccidioidomycosis test for each person (hereafter all dates for coccidioidomycosis tests refer to the specimen collection dates and not the result dates). We then identified systemic antifungal
prescriptions filled ±1 year and systemic antibiotic (specifically antibacterial) prescriptions filled ±3 months after that test date (Table S1). We restricted the time interval for antibiotics to better identify antibiotics likely prescribed for coccidioidomycosis-related symptoms.

We used EventFlow, a data visualization tool developed by University of Maryland,6 to explore, organize, and identify patterns in the longitudinal events (i.e., date of positive coccidioidomycosis test, antifungal prescriptions, and antibiotic prescriptions). We also conducted EventFlow analyses by age group, sex, race/ethnicity, and county of residence. SAS® version 9.3 (SAS Institute, Cary, NC, USA) was used to obtain medians and interquartile ranges for the number of events and time to events.

This study was approved by the KPSC institutional review board. CDC reviewed this study for human subjects’ protections and deemed it to be nonresearch.

We identified 530 persons with coccidioidomycosis (median age: 43 years, range: 3–90). Of these, 334 (63.0%) were male, 209 (39.4%) were Hispanic (regardless of race), 204 (38.5%) were white, 43 (8.1%) were black, 23 (4.3%) were Filipino, 23 (4.3%) were other Asian/Pacific Islander, and 28 (5.3%) were of other race/ethnicity (Table S2). Most were residents of Kern County (n = 277, 52.3%) and Los Angeles County (n = 116, 21.9%).

Overall, 70% of persons received antibiotics in the 3 months before their first positive coccidioidomycosis test, and 36% received them in the 3 months after their first positive coccidioidomycosis test. In contrast, 14% of persons received antifungals in the year before the first positive coccidioidomycosis test, and 79% received them after. In addition, half of all persons with confirmed coccidioidomycosis received ≥1 antibiotic prescription before their first positive test. The top five antibiotics were azithromycin, ceftriaxone, doxycycline, ciprofloxacin, and vancomycin.

The most common first event was antibiotic prescription (n = 369, 69.6%), followed by first positive coccidioidomycosis test (n = 127, 24.0%), and lastly, antifungal prescription (n = 34, 6.4%) (Fig. 1). Filipinos had the highest proportion of antibiotics as the first event (n = 21, 91.3%), compared with other race/ethnicity groups (<82.6%) (Table S2). Persons who had antibiotics first received a median of three antibiotic prescriptions (interquartile range [IQR]: 2–7) at any time during the study period, and a median of 12 days (IQR: 2–33) elapsed between date of first antibiotics and date of first coccidioidomycosis positive test.

The most common event sequence (limited to the first three events) was antibiotic prescription, followed by positive coccidioidomycosis test, followed by antifungal prescription (Fig. 1). Median time between first positive coccidioidomycosis test and antifungals was 7 days (IQR: 2–13).

The following statistics are limited to the 158 (29.8%) persons experiencing the most common sequence. Median time

Figure 1. EventFlow plot of treatment and coccidioidomycosis event sequences. Events are represented by vertical bars and persons (on the y-axis) are aggregated by the order of their events. All events are aligned by the time from first event, which is represented on the x-axis. Bar height represents the proportion of patients with a given sequence, and bar color represents event type. Three events are shown: antibiotic treatment, positive coccidioidomycosis test, and antifungal treatment. Distance between bars represents the median time in days between any two events. All persons experienced ≥1 event type. Subsequent events of the same type were combined into the first event of that type. Time from first event is truncated to 180 days for clarity. The most common first event was antibiotic treatment, and the most common event sequence was antibiotic treatment followed by positive coccidioidomycosis test, and then antifungal treatment. Labels indicated with braces show median times with interquartile ranges between key events for persons who experienced the most common event sequence (i.e., antibiotic prescription, followed by positive coccidioidomycosis test, followed by antifungal prescription). For events that occurred on the same day, antibiotic treatments were considered to have occurred before other events, and antifungal treatments to have occurred before specimen collection of positive tests.
between antibiotic prescription and first positive coccidioidomycosis test was 7 days (IQR: 1–33) for children aged ≤17 years, 8 days (IQR: 1–27) for adults aged 18–50 years, and 20 days (IQR: 6–41) for adults aged ≥51 years. In addition, this median time was >2 times longer for females (22 days; IQR: 5–49) than males (10 days; IQR: 1–23). Filipinos (n = 6; median 37 days; IQR: 19–49) and whites (n = 60; median: 21 days; IQR: 5–43), experienced the longest delays between antibiotic prescription and first positive test, whereas Hispanics (n = 67) experienced the shortest delays (median: 7 days; IQR: 1–23). Filipinos also had the longest median time between positive test and antifungal treatment (11 days; IQR: 8–45). Kern County residents (n = 80) experienced the shortest delays between antibiotic prescription and positive test (median: 4 days; IQR: 1–22) compared with residents of other counties.

In our study, most persons with coccidioidomycosis received antibiotics before their first positive coccidioidomycosis test, including many who received multiple prescriptions and types of antibiotics and experienced diagnosis delays. After positive coccidioidomycosis tests, antibiotic treatment decreased and antifungal treatment increased. This pattern was observed among most groups by age, sex, race/ethnicity, and county of residence.

Similarities in clinical presentation between coccidioidomycosis and other respiratory infections present challenges in accurate diagnosis and appropriate treatment. Antibiotics are ineffective in treating coccidioidomycosis. We found that 70% of persons with coccidioidomycosis received antibiotics within 3 months before their first positive test. We did not investigate whether antibiotic treatments were necessary (i.e., prescribed for unrelated conditions). Similarly, we did not ascertain if the antibiotics were prescribed for the actual coccidioidomycosis episode since we did not review the patient charts. However, at least some of the antibiotics were likely prescribed for coccidioidomycosis symptoms. Moreover, the >50% decrease in antibiotic treatment in the 3 months after positive coccidioidomycosis test strongly suggests empiric treatment for coccidioidomycosis-related conditions.

The optimal treatment of uncomplicated coccidioidomycosis in persons without risk factors for severe or disseminated disease is uncertain; early antifungal treatment is recommended for persons with risk factors, which include immunosuppression (e.g., human immunodeficiency virus (HIV)/AIDS, chemotherapy, or organ transplantation), diabetes mellitus, and black or Filipino race. In our study, Filipinos had the highest percentage of persons receiving antibiotics first; however, our study included a small number of Filipinos, so our results should be interpreted with caution.

We did not assess antimicrobial prescriptions by other risk factors or disease presentations that might influence treatments. Overall, we report a median delay of 12 days between antibiotic prescription and collection date of the first positive specimen.

Because test results are available a median of 6 days (IQR: 4–9) after specimen collection, the actual delays in diagnosis are likely longer than those reported here. Moreover, we did not distinguish between screening and confirmatory tests. After a positive screening test, there is additional delay in confirming the infection and scheduling a follow-up visit. During this time, persons with coccidioidomycosis could potentially still be receiving unnecessary antibiotics. Kern County residents experienced the shortest interval between antibiotic treatment and positive tests, which might reflect greater coccidioidomycosis awareness in Kern County.

We identified likely excessive treatment of persons with coccidioidomycosis with antibiotics. Raising awareness among the public and health care providers may reduce delays in diagnosis and treatment. Clinicians in endemic regions should consider coccidioidomycosis testing early to reduce unnecessary antibiotic use and guide correct treatment.

Supplementary material
Supplementary data are available at MMVOL online.

Acknowledgments
This study was funded by Southern California Permanente Medical Group. The authors thank the patients of Kaiser Permanente for helping to improve care through the use of information collected through our electronic health record systems. The authors thank Byron Robinson, PhD, for helpful insights and comments that greatly improved the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Declaration of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and the writing of the paper.

References